ArticleCNS neuroscience & therapeutics2026
Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsTo compare the real-world effectiveness, surgical and economic outcomes of preoperative rapid antibody clearance therapy (RACT: lymphoplasmapheresis (LPE), efgartigimod (EFG)) versus oral immunosuppressants (Oral IS) in generalized myasthenia gravis (gMG) patients undergoing thymectomy.
methodsThis retrospective study included 78 patients (36 Oral IS, 42 RACT: 25 LPE, 17 EFG). PRIMARY OUTCOME: 3-month postoperative quantitative myasthenia gravis (QMG) score. SECONDARY OUTCOMES: 1-month postoperative exacerbation rate, 3- and 6-month MG activities of daily living (MG-ADL), 6-month QMG, surgical outcomes (operative time, blood loss, postoperative myasthenic crisis (POMC)), perioperative costs (pre- and post-reimbursement). Propensity score overlap weighting balanced covariates. Sensitivity analyses used propensity matching; multiple imputation handled missing data.
resultsAfter weighting, 3-month QMG scores showed no significant difference between RACT and Oral IS groups (mean difference (MD) -0.23, 95% CI: -2.99 to 2.54, p = 0.831) nor between the EFG and LPE subgroups (MD 1.15, 95% CI: -3.97 to 6.26, p = 0.567); similar for MG-ADL. All groups improved over time (p < 0.001). For EFG vs. LPE, 1-month exacerbation rate was 43.3% vs. 26.1% (p = 0.412). No significant between-group differences between EFG and LPE were found in 6-month QMG/MG-ADL scores and surgical outcomes. EFG had higher preoperative pre-reimbursement costs (MD 14,500 CNY, p = 0.026), but no cost differences remained after insurance. Sensitivity analyses confirmed robustness of the primary findings.
conclusionPreoperative RACT effectively reduced QMG in gMG patients, with no significant postoperative medium-term effectiveness and safety differences between RACT and Oral IS. Similarly, no significant differences in postoperative medium-term effectiveness, safety, or post-reimbursement costs were observed between EFG and LPE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.